搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Rhodopseudomonas palustris Arginine--tRNA ligase (argS), partial CSB-YP630344RAAK
CSB-EP630344RAAK
CSB-BP630344RAAK
CSB-MP630344RAAK
CSB-EP630344RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Probable dynein light chain 2, cytoplasmic (dlc-2) CSB-YP630345CXY
CSB-EP630345CXY
CSB-BP630345CXY
CSB-MP630345CXY
CSB-EP630345CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris UDP-3-O-acylglucosamine N-acyltransferase 2 (lpxD2) CSB-YP630346RAAK
CSB-EP630346RAAK
CSB-BP630346RAAK
CSB-MP630346RAAK
CSB-EP630346RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Ribosome-recycling factor (frr) CSB-YP630347RAAK
CSB-EP630347RAAK
CSB-BP630347RAAK
CSB-MP630347RAAK
CSB-EP630347RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris NADH-quinone oxidoreductase subunit D (nuoD) CSB-YP630348RAAK
CSB-EP630348RAAK
CSB-BP630348RAAK
CSB-MP630348RAAK
CSB-EP630348RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Trigger factor (tig) CSB-YP630349RAAK
CSB-EP630349RAAK
CSB-BP630349RAAK
CSB-MP630349RAAK
CSB-EP630349RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris 50S ribosomal protein L9 (rplI) CSB-YP630350RAAK
CSB-EP630350RAAK
CSB-BP630350RAAK
CSB-MP630350RAAK
CSB-EP630350RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Putative Holliday junction resolvase (RPC_2255) CSB-YP630351RAAK
CSB-EP630351RAAK
CSB-BP630351RAAK
CSB-MP630351RAAK
CSB-EP630351RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Phosphomethylpyrimidine synthase (thiC), partial CSB-YP630352RAAK
CSB-EP630352RAAK
CSB-BP630352RAAK
CSB-MP630352RAAK
CSB-EP630352RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Putative ribosomal protein S6 kinase alpha-1 (rskn-1), partial CSB-YP630353CXY
CSB-EP630353CXY
CSB-BP630353CXY
CSB-MP630353CXY
CSB-EP630353CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant UPF0392 protein R07B7.12 (R07B7.12), partial CSB-YP630354CXY1
CSB-EP630354CXY1
CSB-BP630354CXY1
CSB-MP630354CXY1
CSB-EP630354CXY1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Probable 5-hydroxyisourate hydrolase R09H10.3 (R09H10.3) CSB-YP630355CXY
CSB-EP630355CXY
CSB-BP630355CXY
CSB-MP630355CXY
CSB-EP630355CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Alanine--tRNA ligase (alaS), partial CSB-YP630356RAAK
CSB-EP630356RAAK
CSB-BP630356RAAK
CSB-MP630356RAAK
CSB-EP630356RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant 60S ribosomal protein L28 (rpl-28) CSB-YP630357CXY
CSB-EP630357CXY
CSB-BP630357CXY
CSB-MP630357CXY
CSB-EP630357CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Degenerin unc-8 (unc-8), partial CSB-YP630358CXY
CSB-EP630358CXY
CSB-BP630358CXY
CSB-MP630358CXY
CSB-EP630358CXY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Peptidyl-tRNA hydrolase (pth) CSB-YP630359RAAK
CSB-EP630359RAAK
CSB-BP630359RAAK
CSB-MP630359RAAK
CSB-EP630359RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris S-adenosylmethionine synthase 1 (metK1) CSB-YP630360RAAK
CSB-EP630360RAAK
CSB-BP630360RAAK
CSB-MP630360RAAK
CSB-EP630360RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris 50S ribosomal protein L34 (rpmH) CSB-YP630361RAAK
CSB-EP630361RAAK
CSB-BP630361RAAK
CSB-MP630361RAAK
CSB-EP630361RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Succinyl-diaminopimelate desuccinylase (dapE) CSB-YP630362RAAK
CSB-EP630362RAAK
CSB-BP630362RAAK
CSB-MP630362RAAK
CSB-EP630362RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Rhodopseudomonas palustris Glucose-1-phosphate adenylyltransferase (glgC) CSB-YP630363RAAK
CSB-EP630363RAAK
CSB-BP630363RAAK
CSB-MP630363RAAK
CSB-EP630363RAAK-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>